Samsung, Amgen Say Janssen's Crohn's Drug IP Is Not New
Two pharmaceutical companies have challenged new patent protections for Janssen Biotech Inc.'s blockbuster immunosuppressive Stelara, arguing that the latest patent claims for the method of using the drug add nothing new...To view the full article, register now.
Already a subscriber? Click here to view full article